Research programme: epigenetic modulators - Oryzon
Alternative Names: LSD1 inhibitors - Oryzon; OG S1335Latest Information Update: 13 Jul 2023
At a glance
- Originator Oryzon
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
- No development reported Autoimmune disorders; Cancer; Inflammation; Sickle cell anaemia; Viral infections
Most Recent Events
- 13 Jul 2023 ORY 3001 is still in preclinical trials for Unspecified in Spain (PO) (Oryzon pipeline, July 2023)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in Spain (PO)
- 28 Jan 2021 No recent reports of development identified for research development in Autoimmune-disorders in Spain (PO)